• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过下一代测序检测到一种新型ROS1致癌融合基因。

: A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing.

作者信息

Mehta Anurag, Diwan Himanshi, Nathany Shrinidhi, Batra Ullas, Gupta Manoj, Panigrahi Manoj Kumar, Kumar Dushyant, Mattoo Sakshi, Singh Aayushi

机构信息

Department of Laboratory Services and Molecular Diagnostics, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India.

Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India.

出版信息

Clin Pathol. 2024 Aug 12;17:2632010X241269373. doi: 10.1177/2632010X241269373. eCollection 2024 Jan-Dec.

DOI:10.1177/2632010X241269373
PMID:39139859
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11320388/
Abstract

Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners documented in the existing literature. Our report highlights a novel fusion partner of that has demonstrated a conclusive response to the current standard of treatment.

摘要

具有基因重排的晚期非小细胞肺癌（NSCLC）患者对美国食品药品监督管理局批准的酪氨酸激酶抑制剂已显示出显著的治疗反应，现有文献中记录了约40种融合伴侣。我们的报告强调了一种新型融合伴侣，它已证明对当前的治疗标准有确切反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/eed29c5a6b8c/10.1177_2632010X241269373-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/291b1946635e/10.1177_2632010X241269373-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/0486965eb614/10.1177_2632010X241269373-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/20bbe1fce544/10.1177_2632010X241269373-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/7c83f98e9a5f/10.1177_2632010X241269373-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/eed29c5a6b8c/10.1177_2632010X241269373-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/291b1946635e/10.1177_2632010X241269373-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/0486965eb614/10.1177_2632010X241269373-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/20bbe1fce544/10.1177_2632010X241269373-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/7c83f98e9a5f/10.1177_2632010X241269373-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dad/11320388/eed29c5a6b8c/10.1177_2632010X241269373-fig5.jpg

相似文献

1
: A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing.通过下一代测序检测到一种新型ROS1致癌融合基因。
Clin Pathol. 2024 Aug 12;17:2632010X241269373. doi: 10.1177/2632010X241269373. eCollection 2024 Jan-Dec.
2
CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.CEP72-ROS1：下一代测序鉴定的肺腺癌中新型 ROS1 致癌融合变异体。
Thorac Cancer. 2018 May;9(5):652-655. doi: 10.1111/1759-7714.12617. Epub 2018 Mar 8.
3
Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?美国食品药品监督管理局（FDA）要求同步共同开发伴随诊断试剂（CDx）是否会延迟受体酪氨酸激酶抑制剂在全球范围内获批用于ROS1、RET、AXL、PDGFR-α、NTRK1重排的非小细胞肺癌？
Front Oncol. 2014 Apr 1;4:58. doi: 10.3389/fonc.2014.00058. eCollection 2014.
4
Crizotinib in ROS1-rearranged non-small-cell lung cancer.克唑替尼用于ROS1重排的非小细胞肺癌
N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.
5
Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.基于下一代测序技术鉴定的 ROS1 重排非小细胞肺癌的分子和临床病理特征。
Mol Oncol. 2020 Nov;14(11):2787-2795. doi: 10.1002/1878-0261.12789. Epub 2020 Sep 14.
6
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.ROS1 阳性非小细胞肺癌患者在常规临床实践中的特征和结局。
J Thorac Oncol. 2018 Sep;13(9):1373-1382. doi: 10.1016/j.jtho.2018.05.026. Epub 2018 Jun 5.
7
ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.ROS1-ADGRG6：肺腺癌中一种新型 ROS1 致癌融合变异的病例报告及对克唑替尼的反应。
BMC Cancer. 2019 Aug 5;19(1):769. doi: 10.1186/s12885-019-5948-y.
8
Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.非小细胞肺癌ROS1融合重排患者酪氨酸激酶抑制剂治疗的检测方法比较及随访研究
BMC Cancer. 2016 Aug 4;16:599. doi: 10.1186/s12885-016-2582-9.
9
Crizotinib inhibition of positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.克唑替尼抑制晚期非小细胞肺癌中的阳性肿瘤：加拿大视角。
Curr Oncol. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1.
10
A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma.一种与CD74-ROS1融合共存的新型ROS1-FBXL17融合可能提高对克唑替尼的敏感性并延长肺腺癌患者的无进展生存期。
Onco Targets Ther. 2020 Nov 10;13:11499-11504. doi: 10.2147/OTT.S278907. eCollection 2020.

本文引用的文献

1
ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance.ROS1阳性非小细胞肺癌（NSCLC）：生物学、诊断、治疗及耐药性
J Drug Target. 2022 Sep;30(8):845-857. doi: 10.1080/1061186X.2022.2085730. Epub 2022 Jun 14.
2
A Catalog of 5' Fusion Partners in -Positive NSCLC Circa 2020.2020年左右阳性非小细胞肺癌中5'融合伙伴目录
JTO Clin Res Rep. 2020 Apr 28;1(3):100048. doi: 10.1016/j.jtocrr.2020.100048. eCollection 2020 Sep.
3
Incidence of -Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.
印度重排非小细胞肺癌的发病率及克唑替尼在肺腺癌患者中的疗效
Lung Cancer (Auckl). 2020 Feb 24;11:19-25. doi: 10.2147/LCTT.S244366. eCollection 2020.
4
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.恩曲替尼治疗 ROS1 融合阳性非小细胞肺癌：三项 1 期-2 期临床试验的汇总分析。
Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
5
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.洛拉替尼治疗晚期 ROS1 阳性非小细胞肺癌：多中心、开放标签、单臂、1 期-2 期试验。
Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25.
6
Crizotinib in ROS1-rearranged non-small-cell lung cancer.克唑替尼用于ROS1重排的非小细胞肺癌
N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.